Could a chatbot help teens avoid eating disorders?

NCT ID NCT07094503

First seen Jul 15, 2026 · Last updated Jul 16, 2026 · Updated 1 time

Summary

This study tests a digital chatbot program designed to prevent eating disorders in adolescents aged 13 to 19 who are at risk. Participants use the chatbot daily for three months to complete modules based on cognitive-behavioral therapy, focusing on body image and eating behaviors. The goal is to see if the chatbot can reduce weight concerns and related risk factors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
a digital chatbot program called Wysa that provides cognitive-behavioral therapy-based guided self-help modules for eating and body image
What this could lead to
If effective, this chatbot could offer a scalable, accessible way to prevent eating disorders and improve mental health in teens.
What could go wrong
This is a relatively early-phase trial with 400 participants, so results may not apply broadly. The chatbot's effectiveness depends on daily engagement, which may be challenging for some users.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BODY IMAGE DISTURBANCE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Disordered Eating Behavior eating disorder prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Washington University in St. Louis

    RECRUITING

    St Louis, Missouri, 63130, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.